Overview
A Study of LY3200882 in Participants With Solid Tumors
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2022-12-30
2022-12-30
Target enrollment:
0
0
Participant gender:
All
All
Summary
The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Eli Lilly and CompanyTreatments:
Gemcitabine
Paclitaxel
Criteria
Inclusion Criteria:- The participant must have histological or cytological evidence of cancer.
- Have adequate organ function.
- Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1.
- Are able to swallow capsules and tablets.
Exclusion Criteria:
- Have moderate or severe cardiovascular disease.
- Have a serious concomitant systemic disorder.
- Have acute leukemia.